nach oben

Current Cardiology Reports

Erschienen in:

01.06.2019 | Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

Dyslipidemia Profiles in Patients with Peripheral Artery Disease

verfasst von: Aaron W. Aday, Brendan M. Everett

Erschienen in: Current Cardiology Reports | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review of the literature aims to discuss the evidence linking different lipid and apolipoprotein measures to peripheral artery disease.

Recent Findings

Measures of atherogenic dyslipidemia, including elevations in total cholesterol and total cholesterol/high-density lipoprotein cholesterol as well as low levels of high-density lipoprotein cholesterol, are strongly associated with future risk of peripheral artery disease. Compared to coronary artery disease, there are fewer data showing an association between low-density lipoprotein cholesterol and future risk of peripheral artery disease. Novel lipid measures, including nuclear magnetic resonance-derived lipoproteins and oxidized lipids, may lead to better assessments of future peripheral artery disease risk.

Summary

These data highlight the important differences between lipid risk factors for peripheral and coronary artery disease. Improved understanding of these distinctions may lead to new therapeutic options for patients with peripheral artery disease.

Hiatt WR, Goldstone J, Smith SC Jr, McDermott M, Moneta G, Oka R, et al. Atherosclerotic peripheral vascular disease symposium II: nomenclature for vascular diseases. Circulation. 2008;118:2826–9. https://doi.org/10.1161/circulationaha.108.191171.CrossRefPubMed

Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329–40. https://doi.org/10.1016/S0140-6736(13)61249-0.CrossRefPubMed

Criqui MH, Vargas V, Denenberg JO, Ho E, Allison M, Langer RD, et al. Ethnicity and peripheral arterial disease: the San Diego Population Study. Circulation. 2005;112:2703–7. https://doi.org/10.1161/CIRCULATIONAHA.105.546507.CrossRefPubMed

Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015;116:1509–26. https://doi.org/10.1161/CIRCRESAHA.116.303849.CrossRefPubMed

Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from the Framingham Heart Study. Circulation. 1997;96:44–9. https://doi.org/10.1161/01.CIR.96.1.44.CrossRefPubMed

Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J. 2002;143:961–5. https://doi.org/10.1067/mhj.2002.122871.CrossRefPubMed

Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation. 1993;88:837–45. https://doi.org/10.1161/01.CIR.88.3.837.CrossRefPubMed

Kennedy M, Solomon C, Manolio TA, Criqui MH, Newman AB, Polak JF, et al. Risk factors for declining ankle-brachial index in men and women 65 years or older: the Cardiovascular Health Study. Arch Intern Med. 2005;165:1896–902. https://doi.org/10.1001/archinte.165.16.1896.CrossRefPubMed

Meijer WT, Grobbee DE, Hunink MG, Hofman A, Hoes AW. Determinants of peripheral arterial disease in the elderly: the Rotterdam study. Arch Intern Med. 2000;160:2934–8. https://doi.org/10.1001/archinte.160.19.2934.CrossRefPubMed

10.

Allison MA, Criqui MH, McClelland RL, Scott JM, McDermott MM, Liu K, et al. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol. 2006;48:1190–7. https://doi.org/10.1016/j.jacc.2006.05.049.CrossRefPubMed

11.

Fowkes FG, Housley E, Riemersma RA, Macintyre CC, Cawood EH, Prescott RJ, et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh artery study. Am J Epidemiol. 1992;135:331–40. https://doi.org/10.1093/oxfordjournals.aje.a116294.CrossRefPubMed

12.

Ingolfsson IO, Sigurdsson G, Sigvaldason H, Thorgeirsson G, Sigfusson N. A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: a strong relationship to smoking and serum cholesterol--the Reykjavik study. J Clin Epidemiol. 1994;47:1237–43. https://doi.org/10.1016/0895-4356(94)90128-7.CrossRefPubMed

13.

Bowlin SJ, Medalie JH, Flocke SA, Zyzanski SJ, Goldbourt U. Epidemiology of intermittent claudication in middle-aged men. Am J Epidemiol. 1994;140:418–30.CrossRefPubMed

14.

Curb JD, Masaki K, Rodriguez BL, Abbott RD, Burchfiel CM, Chen R, et al. Peripheral artery disease and cardiovascular risk factors in the elderly. The Honolulu Heart Program. Arterioscler Thromb Vasc Biol. 1996;16:1495–500. https://doi.org/10.1016/j.jvs.2007.03.034.CrossRefPubMed

15.

Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285:2481–5. https://doi.org/10.1001/jama.285.19.2481.CrossRefPubMed

16.

Pradhan AD, Shrivastava S, Cook NR, Rifai N, Creager MA, Ridker PM. Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk. Circulation. 2008;117:823–31. https://doi.org/10.1161/CIRCULATIONAHA.107.719369.CrossRefPubMed

17.

Aday AW, Lawler PR, Cook NR, Ridker PM, Mora S, Pradhan AD. Lipoprotein particle profiles, standard lipids, and peripheral artery disease incidence—prospective data from the Women’s Health Study. Circulation. 2018;138:2330–41. https://doi.org/10.1161/circulationaha.118.035432.CrossRefPubMedPubMedCentral

18.

Joosten MM, Pai JK, Bertoia ML, Rimm EB, Spiegelman D, Mittleman MA, et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA. 2012;308:1660–7. https://doi.org/10.1001/jama.2012.13415.CrossRefPubMedPubMedCentral

19.

Bainton D, Sweetnam P, Baker I, Elwood P. Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell prospective heart disease study. Br Heart J. 1994;72:128–32. https://doi.org/10.1136/hrt.72.2.128.CrossRefPubMedPubMedCentral

20.

Smith I, Franks PJ, Greenhalgh RM, Poulter NR, Powell JT. The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia. Eur J Vasc Endovasc Surg. 1996;11:402–8. https://doi.org/10.1016/S1078-5884(96)80170-5.CrossRefPubMed

21.

Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e726–79. https://doi.org/10.1161/CIR.0000000000000471.CrossRefPubMed

22.

Millan J, Pinto X, Munoz A, Zuniga M, Rubies-Prat J, Pallardo LF, et al. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009;5:757–65. https://doi.org/10.2147/VHRM.S6269.CrossRefPubMedPubMedCentral

23.

Mowat BF, Skinner ER, Wilson HM, Leng GC, Fowkes FG, Horrobin D. Alterations in plasma lipids, lipoproteins and high density lipoprotein subfractions in peripheral arterial disease. Atherosclerosis. 1997;131:161–6. https://doi.org/10.1016/S0021-9150(97)06097-8.CrossRefPubMed

24.

Katsilambros NL, Tsapogas PC, Arvanitis MP, Tritos NA, Alexiou ZP, Rigas KL. Risk factors for lower extremity arterial disease in non-insulin-dependent diabetic persons. Diabet Med. 1996;13:243–6. https://doi.org/10.1002/(sici)1096-9136(199603)13:3<243::Aid-dia69>3.0.Co;2-u.CrossRefPubMed

25.

Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ. 2002;325:1139. https://doi.org/10.1136/bmj.325.7373.1139.CrossRefPubMedPubMedCentral

26.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.PubMed

27.

Mora S, Rifai N, Buring JE, Ridker PM. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem. 2009;55:888–94. https://doi.org/10.1373/clinchem.2008.117929.CrossRefPubMedPubMedCentral

28.

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95. https://doi.org/10.1056/NEJMra043430.CrossRefPubMed

29.

Ness J, Aronow WS, Ahn C. Risk factors for symptomatic peripheral arterial disease in older persons in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 2000;48:312–4. https://doi.org/10.1111/j.1532-5415.2000.tb02652.x.CrossRefPubMed

30.

Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373–81. https://doi.org/10.1056/nejm199108083250601.CrossRefPubMed

31.

Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009;119:931–9. https://doi.org/10.1161/CIRCULATIONAHA.108.816181.CrossRefPubMedPubMedCentral

32.

Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112:3375–83. https://doi.org/10.1161/circulationaha.104.532499.CrossRefPubMed

33.

Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294:326–33. https://doi.org/10.1001/jama.294.3.326.CrossRefPubMed

34.

Arsenault BJ, Rana JS, Stroes ES, Despres JP, Shah PK, Kastelein JJ, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol. 2009;55:35–41. https://doi.org/10.1016/j.jacc.2009.07.057.CrossRefPubMed

35.

Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2017;39:763–816. https://doi.org/10.1093/eurheartj/ehx095.CrossRef

36.

Pedersen TR, Kjekshus J, Pyorala K, Olsson AG, Cook TJ, Musliner TA, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol. 1998;81:333–5. https://doi.org/10.1016/S0002-9149(97)00904-1.CrossRefPubMed

37.

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9. https://doi.org/10.1016/S0140-6736(94)90566-5.CrossRef

38.

Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45:645–54. https://doi.org/10.1016/j.jvs.2006.12.054.CrossRef

39.

Arya S, Khakharia A, Binney ZO, DeMartino RR, Brewster LP, Goodney PP, et al. Association of statin dose with amputation and survival in patients with peripheral artery disease. Circulation. 2018;137:1435–46. https://doi.org/10.1161/CIRCULATIONAHA.117.032361.CrossRefPubMedPubMedCentral

40.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22. https://doi.org/10.1056/NEJMoa1615664.CrossRefPubMed

41.

•• Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2017;137:338–50. https://doi.org/10.1161/CIRCULATIONAHA.117.032235 CIRCULATIONAHA.117.032235. This study showed that treatment with evolocumab, a monoclonal antibody against PCSK9, reduces not only cardiovascular but also limb-related events in a high-risk patient population.CrossRefPubMed

42.

Duffield RG, Lewis B, Miller NE, Jamieson CW, Brunt JN, Colchester AC. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomised controlled trial. Lancet. 1983;2:639–42. https://doi.org/10.1016/S0140-6736(83)92527-8.CrossRefPubMed

43.

Blankenhorn DH, Azen SP, Crawford DW, Nessim SA, Sanmarco ME, Selzer RH, et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation. 1991;83:438–47. https://doi.org/10.1097/00008483-199111000-00016.CrossRefPubMed

44.

Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946–55. https://doi.org/10.1056/nejm199010043231404.CrossRefPubMed

45.

Feingold KR, Grunfeld C. Introduction to lipids and lipoproteins. South Dartmouth, MA: MDText.com, Inc.; 2018. Accessed 10/1/2018

46.

Gardner AW, Alaupovic P, Parker DE, Montgomery PS, Roof A, Casanegra AI. Apolipoprotein profiles in subjects with and without peripheral artery disease. Vasc Med. 2013;18:129–35. https://doi.org/10.1177/1358863x13489768.CrossRefPubMedPubMedCentral

47.

Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med. 1997;337:408–16. https://doi.org/10.1056/nejm199708073370607.CrossRefPubMed

48.

Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84:1381–478. https://doi.org/10.1152/physrev.00047.2003.CrossRefPubMed

49.

Smith FB, Lowe GD, Fowkes FG, Rumley A, Rumley AG, Donnan PT, et al. Smoking, haemostatic factors and lipid peroxides in a population case control study of peripheral arterial disease. Atherosclerosis. 1993;102:155–62. https://doi.org/10.1016/0021-9150(93)90157-P.CrossRefPubMed

50.

Bergmark C, Wu R, de Faire U, Lefvert AK, Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol. 1995;15:441–5. https://doi.org/10.1161/01.ATV.15.4.441.CrossRefPubMed

51.

Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, Kronenberg F, et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol. 2006;47:2219–28. https://doi.org/10.1016/j.jacc.2006.03.001.CrossRefPubMed

52.

Bertoia ML, Pai JK, Lee JH, Taleb A, Joosten MM, Mittleman MA, et al. Oxidation-specific biomarkers and risk of peripheral artery disease. J Am Coll Cardiol. 2013;61:2169–79. https://doi.org/10.1016/j.jacc.2013.02.047.CrossRefPubMedPubMedCentral

53.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk prediction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.CrossRefPubMed

Titel: Dyslipidemia Profiles in Patients with Peripheral Artery Disease
verfasst von: Aaron W. Aday
Brendan M. Everett
Publikationsdatum: 01.06.2019
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 6/2019
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-019-1129-5

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Dyslipidemia Profiles in Patients with Peripheral Artery Disease

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Frauen bekommen seltener eine intensive Statintherapie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

Update Kardiologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

Lifestyle Interventions to Prevent Cardiovascular Events After Stroke and Transient Ischemic Attack

Use of Cardiac Imaging to Evaluate Cardiac Function and Pulmonary Hemodynamics in Patients with Heart Failure

Device Closure of Patent Foramen Ovale for Cryptogenic Stroke: Patient Selection and Outcomes According to New Randomized Trials

Treatment Challenges in Patients with Acute Heart Failure and Severe Aortic Valve Stenosis

Ethics and Bias in Clinical Trial Enrollment in Stroke

Refractory Angina: the Current State of Mechanical Therapies

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Frauen bekommen seltener eine intensive Statintherapie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

Update Kardiologie